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Antimitotic agents that interfere with microtubule formation are one of the major classes of cytotoxic 
drugs for cancer treatment. Multiple 2-methyl-4-(3′,4′,5′-trimethoxyphenyl)-5-substituted oxazoles 
and their related 4-substituted-5-(3′,4′,5′-trimethoxyphenyl) regioisomeric derivatives designed 
as cis-constrained combretastatin A-4 (CA-4) analogues were synthesized and evaluated for their 
antiproliferative activity in vitro against a panel of cancer cell lines and, for selected highly active 
compounds, interaction with tubulin, cell cycle effects and in vivo potency. Both these series of 
compounds were characterized by the presence of a common 3′,4′,5′-trimethoxyphenyl ring at either 
the C-4 or C-5 position of the 2-methyloxazole ring. Compounds 4g and 4i, bearing a m-fluoro-p-
methoxyphenyl or p-ethoxyphenyl moiety at the 5-position of 2-methyloxazole nucleus, respectively, 
exhibited the greatest antiproliferative activity, with IC50 values of 0.35-4.6 nM (4g) and 0.5–20.2 nM 
(4i), which are similar to those obtained with CA-4. These compounds bound to the colchicine site 
of tubulin and inhibited tubulin polymerization at submicromolar concentrations. Furthermore, 4i 
strongly induced apoptosis that follows the mitochondrial pathway. In vivo, 4i in a mouse syngeneic 
model demonstrated high antitumor activity which significantly reduced the tumor mass at doses ten 
times lower than that required for CA-4P, suggesting that 4i warrants further evaluation as a potential 
anticancer drug.
Cellular microtubules, undergoing constant assembly and disassembly from α ,β -tubulin heterodimers, are 
key components of the cytoskeleton and are involved in a wide range of cellular functions. Perhaps their most 
important role is formation of the mitotic spindle to direct cell division and proper chromosomal separation1. 
Antimitotic agents represent a major class of cytotoxic drugs for cancer treatment, and tubulin is the target for 
numerous small natural and synthetic molecules that inhibit the formation of the mitotic spindle2–4. Among the 
naturally occurring antimicrotubule agents, one of the most active is the cis-stilbene combretastatin A-4 (CA-4, 
1a, Fig. 1), isolated from the African cape bushwillow Combretum caffrum5. CA-4 inhibits tubulin assembly by 
interacting with β -tubulin at the colchicine site6. The corresponding water soluble prodrug salt, CA-4 disodium 
phosphate (CA-4P, 1b)7, is currently in Phase II trials for anaplastic thyroid cancer8, and it was found to have 
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potent activity in reducing tumor blood flow, thus acting as a vascular disrupting agent (VDA)9. Its structural 
simplicity, along with its ability to selectively damage tumor vasculature, makes CA-4 of great interest from the 
medicinal chemistry point of view10.
Previous SAR studies have demonstrated that both the 3′ ,4′ ,5′ -trimethoxy substitution pattern on the A-ring 
and the cis-olefin configuration at the bridge were fundamental requirements for optimal activity, while some 
B-ring structural modifications were tolerated by the target11. Numerous researchers have undertaken modi-
fication of the relatively unstable cis-double bond of CA-4, which is characterized by the tendency to undergo 
isomerization to the biologically inactive trans-form in solution during storage, administration and metabolism12. 
Thus, to retain the appropriate geometry of the two adjacent aryl groups required for potent bioactivity, chemi-
cally stable cis-restricted derivatives of CA-4 with general structure 2 were obtained by incorporation of the stil-
bene double bond into vicinally diaryl-substituted five-member aromatic heterocyclic rings, such as pyrazole13, 
imidazole13,14, thiazole15, furazan (1,2,5-oxadiazole)16, isoxazole17, oxazole13,14, 1,2,3-thiadiazole18, triazole19 and 
1,2,3,4-tetrazole20.
Among our efforts focused on modification of the cis-double bond of CA-4, we previously described a series 
of 2-methyl-4-(3′ ,4′ ,5′ -trimethoxyphenyl-5-substituted thiazoles with general structure 3 that showed moderate 
antiproliferative activity against a panel of five cancer cell lines. These compounds were one to three orders of 
magnitude less active than CA-4, in terms of molar IC50 values21. These compounds also caused accumulation of 
HeLa and Jurkat cells in the G2/M phase of the cell cycle, as is typical for antimicrotubule agents. Among the syn-
thesized compounds, derivative 3d (R1 = naphth-2-yl) was the most active as an inhibitor of tumor cell growth, 
Figure 1. Lead structures of tubulin polymerization inhibitors. 
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with IC50 values ranging from 33 to 702 nM in the five cell lines examined but was comparable to CA-4 as an 
inhibitor of tubulin polymerization.
In our ongoing effort to discover novel and potent antimicrotubule agents, these results led us to start a phar-
macophore exploration and optimization effort around the 2-methylthiazole derivatives with general formula 
3. Here we describe replacing the thiazole nucleus with the less aromatic and basic bioisosteric equivalent oxaz-
ole ring22, by the preparation of two different regioisomeric series of 2-methyl-4,5-disubstituted oxazole deriv-
atives with general structures 4 and 5. In these two series of designed analogues, obtained by interchanging the 
substitution pattern of ring A and B, we fixed one of the aryl groups as the 3′ ,4′ ,5′ -trimethoxyphenyl moiety, 
identical to the A-ring of CA-4, and examined several substitutions with electron-withdrawing (F and Cl) or 
electron-releasing (Me, OMe, and OEt) groups (EWG or ERG, respectively) on the other aryl moiety, correspond-
ing to the B-ring of CA-4. In addition, for compounds 4a and 5a, the B-ring of CA-4 was replaced with the bulky 
and lipophilic naphth-2-yl moiety.
It has been previously reported that the replacement of the meta-hydroxy group of ring B of CA-4 with halo-
gens such as fluorine or chlorine increased tubulin affinity as well as antiproliferative potency23. Since the meth-
oxy and ethoxy groups proved to be favorable for bioactivity, we maintained one of these substituents at the 
para-position and introduced an additional substituent (F and Cl) at the meta-position of the phenyl ring.
Chemistry
Synthesis of compounds 4a-j and 5a-f was accomplished using a three-step procedure described in Fig. 2. 
2-Methyl-4-substituted oxazole derivatives 8 or 9a-f were prepared by the condensation of 2-bromo-1-(3′ ,4′ ,5′ - 
trimethoxyphenyl)ethanone 6 and the appropriate α -bromo acetophenone 7a-f, respectively, with acetamide at 
150 °C for 2 h. The subsequent chemoselective monobromination at the 5-position of derivatives 8 and 9a-f with 
N-bromosuccinimide in CHCl3 furnished the 2-methyl-4-substituted-5-bromooxazole analogues 10 or 11a-f, 
respectively. Finally, these latter intermediates were subjected to Suzuki cross-coupling reaction with the appro-
priate arylboronic acid under heterogeneous conditions [PdCl2(DPPF), CsF] in 1,4-dioxane at 65 °C, to furnish 
the target 2-methyl-4-(3′ ,4′ ,5′ -trimethoxyphenyl)-5-substituted and isomeric 2-methyl-4-substituted-5-(3′ ,4′ ,5′- 
trimethoxyphenyl)oxazole derivatives 4a-j and 5a-f, respectively.
Figure 2. Reagents. a: CH3CONH2, 150 °C, 2 h; b: N-bromosuccinimide, CHCl3, rt; c: PdCl2(DPPF), 
ArB(OH)2, CsF, 1,4-dioxane. 65 °C. 
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Biological Results and Discussion
In vitro antiproliferative activities. The 2-methyl-4-(3′ ,4′ ,5′ -trimethoxyphenyl)-5-substituted oxazoles 
4a-j and the corresponding isomeric 2-methyl-4-substituted-5-(3′ ,4′ ,5′ -trimethoxyphenyl) oxazole analogues 5a-f 
were evaluated for their antiproliferative activity against a panel of seven human tumor cell lines in comparison 
with the reference compounds CA-4 and 2-methyl-4-(4′ -methoxyphenyl)-5-(3′ ,4’,5′ -trimethoxyphenyl)thiazole 
3e (Table 1). Two of the synthesized compounds, 4g and 4i, had the best antiproliferative activities against these 
cell lines and, overall, were significantly more active than the rest of derivatives as well as than CA-4. Specifically, 
the m-fluoro-p-methoxyphenyl derivative 4g and the p-ethoxyphenyl analogue 4i exhibited IC50 values of 0.35–
4.6 nM and 0.5–20 nM, respectively, as compared with the range 0.8–3100 nM obtained with CA-4. Derivative 
4g was equipotent to CA-4 against Jurkat and SEM cells, while it was from 2- to 940-fold more active against 
the other five cancer cell lines. Compound 4i was 2-fold less active than CA-4 against RS4;11 cells, equipotent to 
CA-4 against Jurkat and SEM cells but 4- to 153-fold more potent against the other four cell lines. Compounds 
4a, 4e, 4j and 5f also inhibited the growth of most of the cancer cell lines at single- to low double-digit nanomolar 
concentrations.
The relative positions of the two aromatic rings on the 2-methyloxazole core seemed to be critical for anti-
proliferative activity. In examining the effect of switching the position of the two aromatic rings at the 4- and 
5-positions on the 2-methyloxazole system (4a vs. 5a, 4b vs. 5b, 4c vs. 5c, 4d vs. 5d, 4e vs. 5e, 4i vs. 5f), we 
observed a considerable difference in potency between the 4′ -(3′ ,4′ ,5’-trimethoxyphenyl) derivatives 4a-e and 4i 
and the regioisomeric 5-(3′ ,4′ ,5′ -trimethoxyphenyl)oxazole counterparts 5a-f. Generally, the latter compounds 
were less active than the former against all the cancer cell lines. Moreover, comparing 3e and 5e, which shared 
common 4′ -methoxyphenyl and 3′ ,4′ ,5′ -trimethoxyphenyl moieties at their 4 and 5-positions, the thiazole deriv-
ative 3e was from 300- to 11-fold less active than its oxazole congener 5e.
The 5-(2′ -naphthyl)oxazole derivative 4a was more active than CA-4 in four of the seven cancer cell lines, with 
activity from single to double digit nanomolar concentrations (IC50: 0.5–73.2 nM). The isomer derivative 5a was 
from 4- to 630-fold less active than 4a, with the greatest reduction of activity against the HT-29 cells.
In comparing the effect of EWG’s or ERG’s at the para-position of the phenyl ring, we observed that com-
pounds with electron-withdrawing substituents such as F (4b and 5b) and Cl (4c and 5c) showed reduced anti-
proliferative activity compared to their counterparts with electron-releasing Me, OMe or OEt moieties (4d-e, 4i 
and 5d-f).
The p-fluorophenyl derivative 4b and its regioisomer 5b were the least active compounds of the series, with 
IC50 values over 9 μ M against all cell lines screened. Increasing the size of the halide from fluorine to chlorine 
lead to an increase of activity with all seven cell lines, which was most pronounced against the RS4;11 cell line. 
Replacing the halogen with the small electron-releasing methyl group at the p-position of the phenyl group (4d) 
improved significantly the antiproliferative activity relative to 4b and 4c, with IC50 values ranging from 25 to 
243 nM, with double digit nanomolar activity against HeLa, A549, HT-29 and RS4;11 cells. The p-tolyl derivative 
4d was from 3- to 28-fold more potent than isomeric counterpart 5d, and this difference was most pronounced 
against A549 and RS4;11.
Replacement of the methyl group with the stronger electron-releasing methoxy group (compounds 4d 
and 4e, respectively) increased the activity from 3- to 9-fold on five of the seven cancer cell lines. For the two 
Compd 
IC50a (nM)
HeLa A549 HT-29 MCF-7 Jurkat RS 4;11 SEM
4a 2.1 ± 0.5 12.6 ± 5.4 0.5 ± 0.1 1.1 ± 0.5 73.2 ± 5.2 14.3 ± 6.2 40.2 ± 11.0
4b > 10000 > 10000 > 10000 > 10000 > 10000 > 10000 9550 ± 2050
4c 2818 ± 169 8785 ± 2309 1397 ± 384 2587 ± 447 5576 ± 888 840 ± 260 2211 ± 256
4d 31.0 ± 16.0 92.3 ± 21.5 53.0 ± 24.6 243.8 ± 74.2 102.2 ± 22.6 25.3 ± 3.2 133.8 ± 39.5
4e 10.8 ± 4.7 179.3 ± 36.3 40.8 ± 19.7 27.7 ± 12.0 18.7 ± 6.0 7.6 ± 2.3 35.6 ± 12.5
4f  > 10000  > 10000  > 10000  > 10000 5233 ± 88.2 5333 ± 166.7 3633 ± 171
4g 2.4 ± 0.6 0.65 ± 0.08 3.3 ± 1.1 2.5 ± 0.7 4.6 ± 1.0 0.35 ± 0.15 3.9 ± 0.8
4h 168.8 ± 75.5 138.3 ± 13.7 207.0 ± 93.0 143.8 ± 64.3 512.2 ± 92.7 47.0 ± 13.9 233.3 ± 34.6
4i 0.9 ± 0.3 0.5 ± 0.1 20.2 ± 8.8 4.5 ± 1.8 4.1 ± 1.1 2.1 ± 0.2 6.1 ± 2.3
4j 4.2 ± 1.3 20.3 ± 11.4 0.9 ± 0.5 1.5 ± 0.6 77.7 ± 6.1 20.2 ± 5.4 51.0 ± 13.5
5a 37.0 ± 14.4 45.2 ± 12.5 315.2 ± 145.3 5.2 ± 2.4 638.3 ± 153.5 249.5 ± 89.3 37.0 ± 14.4
5b > 10000 > 10000 > 10000 > 10000 9000 ± 577.4 > 10000 > 10000
5c 2557 ± 474.6 > 10000 > 10000 > 10000 5250 ± .934 815 ± 405.9 6567 ± 499.6
5d 148.2 ± 55.3 2579 ± 289 523.3 ± 61.8 360.0 ± 52.6 921.7 ± 76.6 635.2 ± 387.1 351.7 ± 77.8
5e 24.0 ± 10.5 243.3 ± 51.5 12.3 ± 5.9 83.8 ± 20.2 43.6 ± 12.3 17.3 ± 4.2 96.6 ± 22.5
5f 2.0 ± 0.8 1.5 ± 0.44 1.9 ± 0.8 0.4 ± 0.08 50.7 ± 10.8 11.9 ± 6.3 13.3 ± 4.2
3e 1978 ± 779.7 2758 ± 1203 3700 ± 263 1933 ± 448 7200 ± 586 2972 ± 738.3 1978 ± 779.7
CA-4 4 ± 0.1 180 ± 50 3100 ± 100 370 ± 100 5 ± 0.6 0.8 ± 0.2 5 ± 0.1
Table 1.  In vitro cell growth inhibitory effects of compounds 3e, 4a-j, 5a-f and CA-4 (1). aIC50 = compound 
concentration required to inhibit tumor cell proliferation by 50%. Values are the mean ± SE from the dose-
response curves of at least three independent experiments carried out in triplicate.
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4-(3′ ,4′ ,5′ -trimethoxyphenyl)oxazole analogues 4e and 4f, the position of methoxy substituent on the 5-phenyl 
ring had a profound influence on antiproliferative activity. Moving the methoxy group from the para- (4e) to the 
meta-position (4f), led to a drastic reduction in antiproliferative activity. Compound 4e was 2- to 3-fold more 
active than the regioisomeric derivative 5e, except in HT-29 cells, where 5e was 3-fold more active than 4e.
Relative to the activity of 4e, the insertion of an additional EWG on the meta-position of the p-methoxyphenyl 
ring had varying effects on antiproliferative activity. The marked influence of an additional fluorine at the 
meta-position of 4e, to furnish the m-F-p-OMe derivative 4g, led to a 4–276-fold increase in antiprolifera-
tive activity, which was most pronounced in the A549 cells. An opposite effect occurred with replacement of 
m-fluorine with m-chlorine, to furnish derivative 4h, which led to a 60–213-fold reduction of activity relative to 
4g. Compound 4h was also 5–60-fold less active than 4e against six of the seven cancer cell lines, the exception 
being the A549 cells.
The p-ethoxyphenyl homologue 4i was 2- to 358-fold more potent than its methoxy counterpart 4e. The 
greatest difference in activity was 358-fold against the A549 cells. Since the p-ethoxy group of 4i was favorable 
for potency, the introduction of an additional electron-withdrawing chlorine group at the meta-position of the 
p-ethoxyphenyl ring, resulting in compound 4j, had variable effects, producing a 5–40-fold reduction in antipro-
liferative activity against five of the cell lines and increased activity against MCF-7 and HT-29 cells. Compound 
4i was from 2- to 12-fold more potent than the isomeric derivative 5f in five of the cell lines, the exceptions being 
the HT-29 and MCF-7 cells, in which 5f was 11- and 3-fold more active than 4i, respectively.
Effects of test compounds 4a, 4i and 5f in non tumoral cells. To obtain a preliminary indication of 
the cytotoxic potential of these derivatives in normal human cells, some of the most active compounds (4a, 4i 
and 5f) were evaluated in vitro against peripheral blood lymphocytes (PBL) from healthy donors. All compounds 
showed an IC50 greater than 10 μ M both in quiescent lymphocytes and in lymphocytes in an active phase of pro-
liferation induced by phytohematoagglutinin (PHA) a mitogenic stimulus (Table 2). Moreover, we also evaluated 
the effects of these compounds on primary cultures of human umbilical endothelial cells (HUVECs), and we 
found that the three compounds were practically inactive, having IC50 values > 100 μ M. These results indicate 
that these compounds have very low toxicity in normal cells in comparison to tumor cells, suggesting potential 
for an excellent therapeutic index.
Inhibition of tubulin polymerization and colchicine binding. A subset of compounds (4a, 4d,e, 4g, 
4i,j, 5a, 5e,f) were evaluated for their in vitro inhibition of tubulin polymerization and for inhibitory effects on 
the binding of [3H]colchicine to tubulin (Table 3). CA-4 was also examined in contemporaneous experiments. In 
the assembly assay, with 10 μ M tubulin, one of the most active antiproliferative agents (4i), along with compound 
4d, were the best inhibitors of tubulin polymerization, with IC50 values of 0.56 and 0.66 μ M, respectively, having 
twice the potency of CA-4 (IC50:1.3 μ M). Derivatives 4a, 4g and 5f showed comparable antitubulin activity to that 
IC50 (μM)a
4a 4i 5f
PBLrestingb 15.5 ± 1.5 14.9 ± 3.5 34.5 ± 4.5
PBLPHAc 21.1 ± 1.2 18.3 ± 1.5 17.7 ± 2.1
HUVECs > 100 > 100 > 100
Table 2.  Cytotoxicity of 4n for nontumoral human cells. Values are the mean ± SEM for three separate 
experiments. aCompound concentration required to reduce cell growth by 50%. bPBL not stimulated with PHA. 
cPBL stimulated with PHA.
Compound
Tubulin assemblya 
IC50 ± S.D (μM)
Colchicine 
binding%b ± S.D
5 μM drug 1 μM drug
4a 1.2 ± 0.1 74 ± 5 47 ± 0.8
4d 0.66 ± 0.0 82 ± 3 55 ± 3
4e 0.95 ± 0.1 78 ± 3 47 ± 4
4 g 1.2 ± 0.0 78 ± 0.5 51 ± 1
4i 0.56 ± 0.1 86 ± 1 62 ± 0.4
4j 1.8 ± 0.1 53 ± 3 n.d.
5a 1.6 ± 0.1 64 ± 4 n.d.
5e 2.6 ± 0.3 54 ± 3 n.d.
5f 1.3 ± 0.1 72 ± 2 n.d.
CA-4 (1) 1.3 ± 0.1 99 ± 0.7 93 ± 0.8
Table 3.  Inhibition of tubulin polymerization and colchicine binding by compounds 4a, 4d-e, 4 g, 4i-j, 5a, 
5e-f and CA-4. n.d. = not determined. aInhibition of tubulin polymerisation. Tubulin was at 10 μ M. bInhibition 
of [3H] colchicine binding. Tubulin and colchicine were at 1 and 5 μ M concentrations, respectively.
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of CA-4, while compound 5e was about half as potent as CA-4. For these new compounds and CA-4, the order of 
inhibitory effects on tubulin assembly was 4i > 4d > 4e > 4g = 4a = 5f = CA-4 > 5a > 4j > 5e.
In the colchicine binding studies, the same compounds potently inhibited the binding of [3H]colchicine to 
tubulin, since 54–86% inhibition occurred with these agents and colchicine both at 5 μ M. Specifically, derivatives 
4d and 4i were slightly less active than CA-4 (86 and 82% inhibition, respectively), which in this experiment 
inhibited colchicine binding by 99%. Inhibition of colchicine binding by compounds 4j, 5a and 5e fell into the 
53–64% range.
While this group of compounds were all highly potent in the biological assays (inhibition of cell growth, 
tubulin assembly and colchicine binding), correlations between these assay types were imperfect. Thus, while 
compound 4g was half as active as an assembly inhibitor as 4d, these two compounds were equipotent in the col-
chicine binding assay. Moreover, compounds 4d and 4i were nearly equipotent as inhibitors of tubulin assembly, 
while 4i was 2-185-fold more active than 4d in its effects on cell growth.
Nevertheless, these studies identified tubulin as the molecular target of these compounds, since those with 
the greatest inhibitory effects on cell growth strongly inhibited tubulin assembly and the binding of colchicine to 
tubulin.
Molecular modelling. The binding mode in the colchicine site of tubulin of the newly prepared 
2-methyloxazole derivatives was elucidated performing a series of molecular docking simulations, following a 
previous reported procedure21. The binding observed for all the derivatives is closely related to the one found 
for the co-crystallized DAMA-colchicine, and it is consistent with those previously reported for different tubu-
lin polymerization inhibitors21,23. The trimethoxyphenyl ring, in both the 4-(para-ethoxyphenyl) and isomeric 
5-(para-ethoxyphenyl)-2-methyloxazole derivatives 4i and 5f, respectively, is in close contact with Cys241, while 
the second substituted phenyl ring occupies a small hydrophobic subpocket (Fig. 3, Panels A and B), with the 
ethoxy substituents lying deep in this pocket. Hydrophobic interactions with the surrounding amino acids (e.g., 
β Met259, β Thr314, β Val181, etc.) of the subpocket stabilize the binding of the molecules in the colchicine site.
Analysis of cell cycle effects. The effects of a 24 h treatment with different concentrations of 4a, 4i and 5f 
on cell cycle progression in Jurkat, and HeLa cells were determined by flow cytometry (Fig. 4, Panels A–F). All 
three compounds caused a significant G2/M arrest in a concentration-dependent manner in the two cell lines 
Figure 3. Proposed binding modes for compounds 4i (carbon atoms in magenta, Fig. 1A) and 5f (carbon 
atoms in pink, Fig. 1B) in the colchicine site. Co-crystallized DAMA-colchicine is shown with carbon atoms 
in green. The hydrophobic subpocket referred to in the text is highlighted with a pink surface.
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examined, with a rise in G2/M cells occurring at a concentration as low as 50 nM, especially with compound 4i, 
while at higher concentrations more than 60% of the cells were arrested in G2/M. The cell cycle arrest in G2/M 
phase was accompanied by a corresponding reduction in cells in the other phases (G1 and S) of the cell cycle. This 
ability of 4i to induce G2/M arrest correlates directly with its strong inhibition of tubulin polymerization. With 
the purpose of evaluating whether 4i arrested cells in mitosis, Hela cells were stained with an immunofluorescent 
antibody to p-histone H3, a well known mitotic marker24, as well as with propidium iodide (PI), and analyzed 
by flow cytometry. As shown in Fig. 5 (Panel A), in which representative histograms are presented, cells arrested 
in M phase by treatment with 4i are readily distinguished from G2 cells by the higher level of p-histone H3. 
Compound 4i induced, after a 24 h incubation, a dose-dependent increase in the percentage of mitotic cells, from 
1.3% observed in the untreated cells to about 32% and 46% at 50 and 100 nM 4i, respectively.
Compound 4i induced alteration of cell cycle checkpoint proteins and induced DNA dam-
age. We investigated the effects of 4i on the expression of proteins involved in regulation of the cell cycle and 
in spindle assembly. Cyclin B1 is involved in the G2 to M transition as a complex with cdc2, and the activation 
of the cdc2/cyclin B1 complex through cdc25c-dependent dephosphorylation of phospho-cdc2 and phospho-
rylation of cyclin B1 triggers cells to enter mitosis25,26. As shown in Fig. 5 (Panel B) a marked increase of cyclin 
B1 occurred in a concentration dependent manner following 24 and 48 h treatments with 4i. On the other hand, 
total cdc25c expression was reduced both at 24 and 48 h after treatment with 100 nM 4i, and we observed the 
Figure 4. Percentage of cells in each phase of the cell cycle in Jurkat (Panels A–C) and HeLa cells (Panels D–F) 
treated with the indicated compounds at the indicated concentrations for 24 h. Cells were fixed and labeled with 
PI and analyzed by flow cytometry as described in the experimental section. Data are shown as mean ± SEM of 
two independent experiments.
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simultaneous appearance of a slowly migrating form of cdc25c, indicating changes in its phosphorylation state. 
Furthermore, in good agreement, the expression of phosphorylated cdc2 decreased, most noticeable after the 24 h 
treatment with 100 nM 4i. These findings are in good agreement with previous results21,23 obtained with other 
antimitotic derivatives and indicate that cdc2/cyclin B1 complexes failed to be activated, preventing cells from 
exiting mitosis, which would eventually lead to apoptotic cell death.
Moreover, since it is well known that prolonged mitotic arrest induces DNA damage27,28 we also examined 
the expression of phosphorylated histone H2A.X at Ser139 (γ H2A.X), a marker of DNA damage29. We observed 
(Fig. 5, Panel B) a great increase of the phosphorylation of γ H2A.X, after a 48 h treatment, suggesting that DNA 
damage occurred following treatment with 4i.
Compound 4i induced apoptosis. To evaluate the mode of cell death induced by 4i, we used an 
annexin-V/PI assay. We treated two cell lines (HeLa and Jurkat) with the test compound with concentrations 
ranging from 15 to 125 nM for 24 or 48 h. As shown in Fig. 6, both Jurkat (Panels A, B) and HeLa (Panels C, D) 
cells treated with 4i showed a significant accumulation of annexin-V positive cells in a concentration dependent 
manner after a 24 h treatment, and the proportions of apoptotic cells further increased at 48 h. Note that 4i caused 
the appearance of 70% apoptotic cells at 60 nM in Hela cells, while in the leukemic cell line we observed a lower 
value (40%) after a 24 h treatment, in good agreement with its cytotoxic activity.
Compound 4i induced apoptosis through the mitochondrial pathway. Since many combretastatin 
analogues cause apoptosis following the mitochondrial pathway [19c, refs 20 and 23] we investigated if 4i also 
induced mitochondrial depolarization. Mitochondrial potential was monitored by flow cytometry using the flu-
orescent dye JC-1. We treated both Hela and Jurkat cells with 4i at 50 or 100 nM for 24 or 48 h. As shown in Fig. 7 
(Panels A and B), both Jurkat and HeLa cells treated with 4i exhibited a marked increase in the percentage of cells 
with low Δ ψ mt in a time dependent manner, paralleling the results obtained with the annexin-V apoptotic assay. 
Since it is well known that dissipation of mitochondrial potential is associated with mitochondrial production of 
reactive oxygen species (ROS)30,31, we also evaluated whether ROS production increased after treatment with 4i. 
We utilized the dye 2,7-dichlorodihydrofluorescein diacetate (H2-DCFDA), which is oxidized to the fluorescent 
compound dichlorofluorescein (DCF) upon ROS induction.
The results shown in Fig. 7 (Panels C and D) indicate that 4i induced ROS production in comparison with the 
amounts observed in control cells, in both Jurkat and HeLa cells, moving from about 4% of DCF positive cells in 
untreated samples to about 25–30% in treated cells at 100 nM, the highest concentration examined. These results 
are in excellent agreement with the dissipation of Δ ψ mt described above.
Figure 5. (A) Representative histograms of mitotic cells with phosphorylated histone-H3 after treatment 
with 4i at the indicated concentrations in HeLa cells. Data are representative of two experiments with similar 
results. (B) Effect of 4i on cell cycle checkpoint proteins and expression of p-H2A.XSer139. HeLa cells were treated 
for 24 or 48 h with the indicated concentrations of 4i. The cells were harvested and lysed for detection of the 
expression of the indicated protein by western blot analysis. To confirm equal protein loading, each membrane 
was stripped and reprobed with anti-β -actin antibody.
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Compound 4i induced PARP cleavage and down regulation of anti-apoptotic proteins. To fur-
ther study the apoptotic process induced by 4i, we analyzed the cleavage of PARP a typical marker of apoptosis32. 
As shown in Fig. 8, immunoblot analysis of Hela cells treated with 50 or 100 nM 4i indicated the activation PARP 
after both 24 and 48 h, as evidenced by the appearance of its cleavage fragments.
We also investigated the expression of two anti-apoptotic proteins, Mcl-1 and XIAP. Mcl-1 is a member of the 
Bcl-2 family of anti-apoptotic proteins. Mcl-1 is overexpressed in many cancers, and it has been reported that 
sensitivity to antimitotic drugs is regulated by Mcl-1 levels33. As shown in Fig. 8, the expression of Mcl-1 was only 
slightly decreased at the highest 4i concentration used (100 nM).
On the other hand, XIAP, also a member of the IAP family (inhibitors of apoptosis protein)34, was significantly 
reduced after both the 24 and 48 h treatments, suggesting that 4i treatment induced downregulation of these 
proteins to disable their anti-apoptotic function.
Evaluation of antivascular activity of 4i and 5f. Since many tubulin binding agents, including CA-4, 
are endowed with vascular disrupting activity [9c], we investigated in vitro the potential anti-vascular activity of 
compounds 4i and 5f. We tested the anti-vascular effects in HUVECs, evaluating the ability of the compounds 
to i) interfere with angiogenesis by inhibiting endothelial cell migration and ii) to interfere with the process of 
capillary-like tube formation. Confluent HUVEC monolayers were scraped with a pipette tip and cellular migra-
tion induced to repair the wound was followed by optical microscopy, and the percentage of reduction of wound 
healing was calculated at different times35. As shown in Fig. 9 (Panels A and B), after only a 6 h treatment, cell 
migration was significantly reduced at 100 nM compound 4i or 5f. This significant reduction was maintained 
for a 24 h treatment as well. In contrast, CA-4 was significantly active even at 10 nM, after both the 6 and 24 h 
treatments.
Endothelial cells seeded on Matrigel are able to form a capillary network miming the first angiogenesis steps36. 
This network is a useful experimental model to assess the action of molecules on vascular morphogenesis.
The antivascular effect induced by the tested compounds is shown in Fig. 9 (Panels C and D). In this case, 
we evaluated the pictures taken after a 24 h incubation by optical microscopy (Fig. 9, Panel C), and a quantita-
tive analysis was carried out studying two dimensional (percent area covered by HUVECs and total length of 
HUVECs network per field) and two topological parameters (number of meshes and branching points per field).
Compounds 4i and 5f did not show a significant antivascular effect on Matrigel preformed tubular structures 
(Fig. 9, Panel D), even at the highest concentration used (100 nM). In this assay, CA-4 showed, as expected, a 
significant antivascular activity even at 10 nM. Our findings suggest that these compounds do not possess a good 
antivascular profile in comparison to the well known activity of CA-4, since some effects, in particular cellular 
migration, occurred at a concentration higher than that required for CA-4.
Figure 6. Flow cytometric analysis of apoptotic cells after treatment of Jurkat cells (Panels A and B) or HeLa 
cells (Panels C and D) with 4i at the indicated concentrations after incubation for 24 or 48 h. The cells were 
harvested and labeled with annexin-V-FITC and PI and analyzed by flow cytometry. Data are represented as 
mean ± SEM of three independent experiments.
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Compound 4i induced tumor growth reduction in a mouse allograft tumor model. The antitu-
mor effect in vivo of compound 4i was evaluated in an allograft tumor model developed in mice37. This model 
consists of the use of B16 murine melanoma cells that are injected in the flank of mice. Consequently, in pre-
liminary experiments we wanted to verify the effectiveness of the compound 4i on this murine tumor line. The 
compound had an IC50 of 15.6 ± 1.9 nM measured by the MTT assay, indicating that its cytotoxic potency was 
similar to that found in human tumor cell lines (see Table 1). In addition, we also evaluated, if in this cell line, 
the compound was able to arrest cells in the G2/M phase of the cell cycle and to induce apoptosis. As shown in 
Fig. 10 (Panels A and B), 4i, as was observed in the human tumor cell lines, induced a G2/M arrest and a strong 
apoptotic response at low concentrations (50–100 nM). These results indicated that the allogeneic mouse model 
Figure 7. Assessment of mitochondrial membrane potential (Panels A and B) and ROS production after 
treatment of Jurkat cells (A and C) or HeLa cells (B and D) with compound 4i. Cells were treated with the 
indicated concentration of compound for 24 or 48 h and then stained with the fluorescent probes JC-1 or 
H2-DCFDA and analyzed by flow cytometry. Data are presented as mean ± S.E.M. for three independent 
experiments.
Figure 8. Western blot analysis of caspase-3, PARP, Mcl-1 and XIAP after treatment of HeLa cells with 4i at 
the indicated concentrations and for the indicated times. To confirm equal protein loading, each membrane 
was stripped and reprobed with anti-β -actin antibody.
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used was fully relevant to the evaluation of 4i in vivo. Thus, 4i was administered by the intraperitoneal route every 
other day, at two different doses (3.0 and 7.5 mg/kg). As reference compound, CA-4P (1b) was used at 30 mg/kg.
As shown in Fig. 10 (panel C), after a six day treatment (doses administered on days 9, 11 and 14), 4i was able 
to significantly reduce tumor burden in a dose-dependent manner, even at the lowest dose tested (3.0 mg/kg). We 
Figure 9. Antivascular activity of compounds 4i and 5f. (A) Representative images of confluent HUVEC 
monolayers that were scratch wounded and treated with vehicle (Ctr) or 10 or 100 nM 4i, as indicated, after 
0, 6 or 24 h from the scratch. After different times, cells were photographed (10x magnification), and the 
scratch width was quantified (Panel B). CA-4 was chosen as reference compound. Data are presented as 
the mean ± SEM of three independent experiments. ***p < 0.01 vs control. (C) Disruption of capillary-like 
structures. Representative images of HUVEC cells that were incubated on Matrigel until the formation of 
capillary-like tubes. The disrupting effects of 10 or 100 nM 4i are shown (10x magnification). D. Quantification 
of the effect of compounds 4i, 5f and CA-4 on dimensional and topological parameters of HUVEC morphology 
in comparison to time zero. Data are presented as the mean ± SEM of three independent experiments. *p < 0.01 
vs Ctr.
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observed reduction in tumor mass of 34.9, and 52.5% at the doses of 3.0 and 7.5 mg/kg, respectively. The reference 
compound CA-4P at 30 mg/kg induced only a 28.0% reduction in tumor mass. Notably, the in vivo efficacy clearly 
indicate an increased antitumor efficacy of 4i as compared with CA-4P (in both weight and molar terms). Even 
at the highest dose, 4i did not show any sign of toxicity and did not cause a decrease in animal body weight (data 
not shown).
Conclusions
The isomerization of the cis-double bond of CA-4 to its trans-form in solution is one of the major disadvantages 
of this molecule. The instability of the Z-double bond of CA-4 has been resolved by incorporating the stilbene 
double bond into the structure of five-member heterocyclic rings. The bioisosteric equivalence between oxazole 
and thiazole prompted us to synthesize by a three-step procedure two novel series of 2-methyl-4,5-disubstituted 
oxazole derivatives with general formulas 4 and 5, in which the oxazole ring replaced the thiazole system of pre-
viously published analogues with general structure 3 and could serve as a suitable mimic to retain the bioactive 
configuration afforded by the cis-double bond present in CA-4. For both these series of compounds, the 3′ ,4′ ,5′ 
-trimethoxyphenyl and 2-methyloxazole rings mimic the ring A and cis-double bond of CA-4, respectively, while 
a naphth-2-yl or phenyl ring substituted with electron-releasing or electron-withdrawing groups was utilized as 
a B-ring surrogate to mimic the 3′ -hydroxy-4′ -methoxyphenyl group in CA-4. Comparing compounds with the 
same aryl substitution, the 2-methyl-4-(3′ ,4′ ,5′ -trimethoxyphenyl)oxazole derivatives were more active than their 
isomeric 2-methyl-5-(3′ ,4′ ,5′ -trimethoxyphenyl)oxazole counterparts. The results indicated that 2-methyloxazole 
derivatives 4a, 4d-e, 4i and 5e exhibited more highly potent antiproliferative activity than the corresponding 
2-methylthiazole analogues 3a-e previously described. These marked differences were maintained in all the bio-
logical evaluations performed. In particular, it is important to underline that 4i has very low toxicity in non 
tumoral cell lines such as PBLs and HUVECs. Although preliminary investigations regarding the potential anti-
vascular activity of these new oxazoles derivatives indicated that they are not potent vascular disrupting agents, 
in vivo experiments demonstrated that 4i had excellent antitumor activity that was evident at lower doses than 
CA-4P and in the absence of obvious toxicity. In summary, the biological characterization of compound 4i pro-
vides compelling evidence to support its further development as an anticancer drug.
Figure 10. Panel A. Effect of compound 4i on cell cycle of BL6-B16 murine melanoma cells treated with the 
compounds at the indicated concentrations for 24 h. Cells were fixed and labeled with PI and analyzed by 
flow cytometry as described in the experimental section. Data are shown as mean ± SEM of two independent 
experiments. Panel B. Flow cytometric analysis of apoptotic cells after treatment of BL6-B16 murine melanoma 
with 4i at the indicated concentrations after incubation for 24 or 48 h. The cells were harvested and labeled 
with annexin-V-FITC and PI and analyzed by flow cytometry. Data are represented as mean ± SEM of two 
independent experiments. Panel C. Inhibition of mouse allograft growth in vivo by compound 4i. Male C57BL/6 
mice were injected subcutaneously at their dorsal region with 107 BL6-B16 murine melanoma cells. Tumor-
bearing mice were administered the vehicle, as control, or 3 or 7.5 mg/kg of 4i or CA-4P as reference compound 
at the dose of 30 mg/kg. Injections were given intraperitoneally at the days indicated by the arrows. Data are 
presented as mean ± SEM of tumor volume at each time point for 5 animals per group. ***p < 0.001 vs. control.
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Experimental Section
Chemistry. Materials and Methods. 1H and 13C NMR data were obtained with a Varian VXR 200 spec-
trometer and a Varian Mercury Plus 400 spectrometer, respectively. Peak positions are given in parts per mil-
lion (δ) downfield, and J values are given in hertz. Positive-ion electrospray ionization (ESI) mass spectra were 
recorded on a double-focusing Finnigan MAT 95 instrument with BE geometry. Melting points (mp) were deter-
mined on a Buchi-Tottoli apparatus and are uncorrected. The purity of tested compounds was determined by 
combustion elemental analyses conducted by the Microanalytical Laboratory of the Chemistry Department of 
the University of Ferrara with a Yanagimoto MT-5 CHN recorder elemental analyzer. All tested compounds 
yielded data consistent with a purity of at least 95% as compared with the theoretical values. TLC was carried out 
using glass plates coated with silica gel 60 F254 by Merck, and compounds were visualized by UV detection or with 
aqueous KMnO4. Flash column chromatography was performed using 230–400 mesh silica gel and the indicated 
solvent system. Organic solutions were dried over anhydrous Na2SO4. Solvents and reagents that are commer-
cially available were purchased from Aldrich (Sigma-Aldrich) or Alfa Aesar (Johnson Matthey Company) and 
were used without further purification unless otherwise noted.
General procedure A for the preparation of compounds 8 and 9a-f. A mixture of the appropri-
ate 2-bromoacetophenone 6 or 7a-f (4 mmol) and acetamide (708 mg, 12 mmol) was heated to 150 °C for 2 h. 
After this time, the mixture was cooled to room temperature, treated with a 2 M aqueous solution of Na2CO3 
(10 mL), and the suspension was carefully adjusted to pH 12 with Na2CO3. The mixture was extracted with EtOAc 
(2 × 20 mL), the combined organic phase was washed with water (10 mL) and brine (10 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel.
4-(3,4,5-Trimethoxyphenyl)-2-methyloxazole (8). Following general procedure A, the crude residue 
purified by flash chromatography, using EtOAc:petroleum ether 1:1 (v:v) for elution, yielded 8 as a white solid. 
Yield 72%, mp 98–100 °C. 1H-NMR (CDCl3) δ : 2.57 (s, 3H), 3.87 (s, 3H), 3.93 (s, 6H), 6.96 (s, 2H), 7.79 (s, 1H). 
MS (ESI): [M + 1]+ = 250.3.
2-Methyl-4-(naphthalen-3-yl)oxazole (9a). Following general procedure A, the crude residue purified 
by flash chromatography, using EtOAc:petroleum ether 1:9 (v:v) for elution, yielded 9a as an orange solid. Yield 
71%, mp 72–73 °C. 1H-NMR (CDCl3) δ : 2.58 (s, 3H), 7.49 (m, 2H), 7.74 (dd, J = 8.6 and 1.8 Hz, 1H), 7.93 (m, 4H), 
8.28 (s, 1H). MS (ESI): [M + 1]+ = 210.3.
4-(4-Fluorophenyl)-2-methyloxazole (9b). Following general procedure A, the crude residue purified 
by flash chromatography, using EtOAc:petroleum ether 3:7 (v:v) for elution, yielded 9b as an orange solid. Yield 
61%, mp 54–56 °C. 1H-NMR (CDCl3) δ : 2.53 (s, 3H), 7.08 (t, J = 8.8 Hz, 2H), 7.65 (dd, J = 8.8 Hz, 2H), 7.76 (s, 
1H). MS (ESI): [M + 1]+ = 178.2.
4-(4-Chlorophenyl)-2-methyloxazole (9c). Following general procedure A, the crude residue purified 
by flash chromatography, using EtOAc:petroleum ether 2:8 (v:v) for elution, yielded 9c as a white solid. Yield 62%, 
mp 88–90 °C. 1H-NMR (CDCl3) δ : 2.54 (s, 3H), 7.36 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 8.8 Hz, 2H), 7.81 (s, 1H). MS 
(ESI): [M + 1]+ = 194.7.
2-Methyl-4-p-tolyloxazole (9d). Following general procedure A, the crude residue purified by flash chro-
matography, using EtOAc:petroleum ether 3:7 (v:v) for elution, yielded 9d as an orange solid. Yield 63%, mp 
49–51 °C. 1H-NMR (CDCl3) δ : 2.36 (s, 3H), 2.53 (s, 3H), 7.18 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.77 (s, 
1H). MS (ESI): [M + 1]+ = 174.2.
4-(4-Methoxyphenyl)-2-methyloxazole (9e). Following general procedure A, the crude residue puri-
fied by flash chromatography, using EtOAc:petroleum ether 4:6 (v:v) for elution, yielded 9e as a white solid. Yield 
67%, mp 68–70 °C. 1H-NMR (CDCl3) δ : 2.66 (s, 3H), 3.84 (s, 3H), 6.94 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 
7.77 (s, 1H). MS (ESI): [M + 1]+ = 190.1.
4-(4-Ethoxyphenyl)-2-methyloxazole (9f). Following general procedure A, the crude residue purified 
by flash chromatography, using EtOAc:petroleum ether 3:7 (v:v) for elution, yielded 9 f as a cream-colored solid. 
Yield 62%, mp 76–79 °C. 1H-NMR (CDCl3) δ : 1.42 (t, J = 6.8 Hz, 3H), 2.56 (s, 3H), 4.01 (q, J = 6.8 Hz, 2H), 6.90 (d, 
J = 8.8 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H), 7.73 (s, 1H). MS (ESI): [M + 1]+ = 204.3.
General procedure B for the preparation of compounds 10 and 11a-f. A solution of the appro-
priate 2-methyl-4-aryloxazole 8 or 9a-f (4 mmol) in anhydrous CHCl3 (20 mL) was cooled to 0 °C, then 
N-bromosuccinimide (783 mg, 4.4 mmol) was added in small portions. The reaction mixture was allowed to 
warm slowly to room temperature. After 2 h, the resulting mixture was diluted with CH2Cl2 (20 mL), washed with 
a saturated solution of NaHCO3 (10 mL), brine (10 mL), dried (MgSO4) and evaporated. The residue was purified 
by column chromatography on silica gel.
5-Bromo-4-(3,4,5-trimethoxyphenyl)-2-methyloxazole (10). Following general procedure B, the 
crude residue purified by flash chromatography, using EtOAc:petroleum ether 4:6 (v:v) for elution, furnished 10 
as a white solid. Yield 73%, mp 108–110 °C. 1H-NMR (CDCl3) δ : 2.54 (s, 3H), 3.88 (s, 3H), 3.93 (s, 6H), 7.20 (s, 
2H). MS (ESI): [M]+ = 327.4, [M + 2]+ = 329.5.
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5-Bromo-2-methyl-4-(naphthalen-3-yl)oxazole (11a). Following general procedure B, the crude res-
idue purified by flash chromatography, using ethyl acetate:petroleum ether 2:8 (v:v) for elution, yielded 11a as a 
pink solid. Yield 67%, mp 89–91 °C. 1H-NMR (CDCl3) δ : 2.56 (s, 3H), 7.49 (m, 2H), 7.82 (m, 4H), 8.05 (dd, J = 8.8 
and 1.6 Hz, 1H). MS (ESI): [M]+ = 268.2, [M + 2]+ = 270.1.
5-Bromo-4-(4-fluorophenyl)-2-methyloxazole (11b). Following general procedure B, the crude res-
idue purified by flash chromatography, using EtOAc:petroleum ether 2:8 (v:v) for elution, furnished 11b as an 
orange oil. Yield 58%. 1H-NMR (CDCl3) δ : 2.51 (s, 3H), 7.07 (d, J = 8.8 Hz, 2H), 7.87 (dd, J = 9.2 and 9.0 Hz, 2H). 
MS (ESI): [M]+ = 256.1, [M + 2]+ = 258.1.
5-Bromo-4-(4-chlorophenyl)-2-methyloxazole (11c). Following general procedure B, the crude 
residue purified by flash chromatography, using EtOAc:petroleum ether 4:6 (v:v) for elution, furnished 11c as 
an orange solid. Yield 71%, mp 61–62 °C. 1H-NMR (CDCl3) δ : 2.52 (s, 3H), 7.38 (d, J = 8.4 Hz, 2H), 7.87 (d, 
J = 8.4 Hz, 2H). MS (ESI): [M]+ = 272.6, [M + 2]+ = 274.6.
5-Bromo-2-methyl-4-p-tolyloxazole (11d). Following general procedure B, the crude residue purified 
by flash chromatography, using ethyl acetate:petroleum ether 3:7 (v:v) for elution, yielded 11d as white solid. 
Yield 58%, mp 72–74 °C. 1H-NMR (CDCl3) δ : 2.38 (s, 3H), 2.53 (s, 3H), 7.21 (d, J = 8.2 Hz, 2H), 7.84 (d, J = 8.2 Hz, 
2H), 7.77 (s, 1H). MS (ESI): [M]+ = 252.2, [M + 2]+ = 254.2.
n5-Bromo-4-(4-methoxyphenyl)-2-methyloxazole (11e). Following general procedure B, the crude 
residue purified by flash chromatography, using EtOAc:petroleum ether 2:8 (v:v) for elution, furnished 11e as a 
white solid. Yield 67%, mp 78–80 °C. 1H-NMR (CDCl3) δ : 2.54 (s, 3H), 3.85 (s, 3H), 6.94 (d, J = 9.2 Hz, 2H), 7.85 
(d, J = 9.2 Hz, 2H). MS (ESI): [M]+ = 266.1, [M + 2]+ = 268.0.
5-Bromo-4-(4-ethoxyphenyl)-2-methyloxazole (11f). Following general procedure B, the crude res-
idue purified by flash chromatography, using EtOAc:petroleum ether 3:7 (v:v) for elution, yielded 11f as a pink 
solid. Yield 59%, mp 64–66 °C. 1H-NMR (CDCl3) δ : 1.44 (t, J = 7.2 Hz, 3H), 2.52 (s, 3H), 4.01 (q, J = 7.2 Hz, 
2H), 6.92 (dd, J = 6.8 and 2.2 Hz, 2H), 7.62 (dd, J = 6.8 and 2.2 Hz, 2H), 7.73 (s, 1H). MS (ESI): [M]+ = 282.2, 
[M + 2]+ = 284.2.
General procedure C for the synthesis of compounds 4a-j and 5a-f. A stirred suspension of 
5-bromo-2-methyl-4-aryloxazole 10 or 11a-f (0.5 mmol) and the appropriate arylboronic acid (0.75 mmol) in 
dioxane (6 mL containing 2 drops of water) was degassed under a stream of N2 over 10 min, then treated with 
PdCl2(DPPF) (41 mg, 0.05 mmol) and CsF (190 mg, 1.25 mmol). The reaction mixture was heated under N2 at 
45 °C for 30 min, then at 65 °C for 6 h. The reaction mixture was cooled to ambient temperature, diluted with 
CH2Cl2 (10 mL), filtered through a pad of celite and evaporated in vacuo. The residue was dissolved with CH2Cl2 
(15 mL), and the resultant solution was washed sequentially with water (5 mL) and brine (5 mL). The organic layer 
was dried and evaporated, and the residue was purified by column chromatography on silica gel.
4-(3,4,5-Trimethoxyphenyl)-2-methyl-5-(naphthalen-3-yl)oxazole (4a). Following general pro-
cedure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 1:1 
as eluent, affording compound 4a as a yellow solid. Yield: 58%, mp 104–116 °C. 1H-NMR (CDCl3) δ : 2.66 (s, 
3H), 3.76 (s, 6H), 3.83 (s, 3H), 6.96 (s, 2H), 7.51 (m, 2H), 7.68 (dd, J = 8.8 and 1.2 Hz, 1H), 7.84 (m, 3H), 8.1 (d, 
J = 1.2 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ : 13.97, 56.16 (2C), 60.98, 105.02 (2C), 109.98, 120.17, 121.16, 
122.02, 124.12, 125.94, 126.80, 126.86, 127.81, 128.20, 133.13, 137.08, 139.75, 145.48, 153.38 (2C), 160.79. MS 
(ESI): [M]+ = 375.5. Anal. (C23H21NO4) C, H, N.
5-(3,4,5-Trimethoxyphenyl)-4-(4-fluorophenyl)-2-methyloxazole (4b). Following general proce-
dure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 1:1 as 
eluent, affording compound 4b as a white solid. Yield: 62%, mp 142–144 °C. 1H-NMR (CDCl3) δ : 2.60 (s, 3H), 3.78 
(s, 6H), 3.83 (s, 3H), 6.85 (s, 2H), 7.06 (t, J = 8.8 Hz, 2H), 7.60 (dd, J = 8.8 and 8.6 Hz, 2H). 13C NMR (100 MHz, 
CDCl3) δ : 14.02, 56.18 (2C), 61.03, 104.87 (2C), 115.72, 115.93, 125.14, 127.29, 128.78, 128.86, 134.56, 138.08, 
144.40, 153.44 (2C), 160.36 and 163.98 (J = 144.8 Hz), 161.49. MS (ESI): [M]+ = 343.4. Anal. (C19H18FNO4) C, 
H, N.
5-(3,4,5-Trimethoxyphenyl)-4-(4-chlorophenyl)-2-methyloxazole (4c). Following general proce-
dure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 6:4 as 
eluent, affording compound 4c as a white solid. Yield: 64%, mp 158–160 °C. 1H-NMR (CDCl3) δ : 2.66 (s, 3H), 3.80 
(s, 6H), 3.84 (s, 3H), 6.87 (s, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 
: 14.04, 56.21 (2C), 61.04, 105.03 (2C), 126.92, 127.49, 127.82 (2C), 128.90 (2C), 134.32, 135.46, 138.18, 144.14, 
153.47 (2C), 160.47. MS (ESI): [M]+ = 359.6. Anal. (C19H18ClNO4) C, H, N.
4-(3,4,5-Trimethoxyphenyl)-2-methyl-5-p-tolyloxazole (4d). Following general procedure C, the 
residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 6:4 as eluent, afford-
ing compound 4d as a white solid. Yield: 51%, mp 110–112 °C. 1H-NMR (CDCl3) δ : 2.38 (s, 3H), 2.64 (s, 3H), 3.79 
(s, 6H), 3.83 (s, 3H), 6.91 (s, 2H), 7.18 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H). 13C NMR (100 MHz, CDCl3) 
δ : 14.02, 21.45, 56.16 (2C), 61.01, 104.90 (2C), 126.18, 126.72 (2C), 127.89, 129.32 (2C), 134.29, 137.85, 138.66, 
145.44, 153.32 (2C), 159.99. MS (ESI): [M]+ = 339.7. Anal. (C20H21NO4) C, H, N.
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4-(3,4,5-Trimethoxyphenyl)-5-(4-methoxyphenyl)-2-methyloxazole (4e). Following general 
procedure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 
1:1 as eluent, affording compound 4a as a white solid. Yield: 59%, mp 134–136 °C. 1H-NMR (CDCl3) δ : 2.63 (s, 
3H), 3.79 (s, 6H), 3.80 (s, 3H), 3.84 (s, 3H), 6.90 (s, 2H), 6.91 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H). 13C 
NMR (100 MHz, CDCl3) δ : 13.96, 55.33, 56.06 (2C), 60.93, 104.68 (2C), 113.98 (2C), 121.52, 127.86, 128.36 (2C), 
133.57, 137.68, 145.21, 153.25 (2C), 159.70, 160.78. MS (ESI): [M]+ = 355.6. Anal. (C20H21NO5) C, H, N.
5-(3,4,5-Trimethoxyphenyl)-4-(3-methoxyphenyl)-2-methyloxazole (4f). Following general pro-
cedure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 1:1 as 
eluent, affording compound 4f as a white solid. Yield: 64%, mp 104–106 °C. 1H-NMR (CDCl3) δ : 2.61 (s, 3H), 3.78 
(s, 6H), 3.79 (s, 3H), 3.87 (s, 3H), 6.87 (td, J = 8.4, 2.8 and 1.2 Hz, 1H), 6.91 (s, 2H), 7.16 (dd, J = 2.8 and 1.2 Hz, 
1H), 7.21 (dt, J = 8.0 and 1.2 Hz, 1H), 7.27 (dd, J = 8.4 and 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ : 14.12, 
55.42, 56.26 (2C), 60.47, 61.02, 105.16 (2C), 112.06, 114.78, 119.27, 126.71, 129.79, 134.35, 138.19, 145.28, 153.38 
(2C), 159.77, 160.61. MS (ESI): [M]+ = 355.6. Anal. (C20H21NO5) C, H, N.
5-(3-Fluoro-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-2-methyloxazole (4g). Following 
general procedure C, the residue was purified by flash chromatography on silica gel using light petroleum 
ether:EtOAc 1:1 as eluent, affording compound 4g as a white solid. Yield: 69%, mp 127–129 °C. 1H-NMR (CDCl3) 
δ : 2.66 (s, 3H), 3.80 (s, 6H), 3.84 (s, 3H), 3.88 (s, 3H), 6.89 (s, 2H), 6.96 (d, J = 8.2 Hz, 1H), 7.36 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ : 14.11, 55.26 (2CC), 56.33, 61.04, 105.01 (2C), 113.29, 114.47, 121.77, 123.02, 127.04, 134.10, 
138.15, 144.14, 147.93, 150.96, 153.44 (2C), 160.28. MS (ESI): [M]+ = 373.5. Anal. (C20H20FNO5) C, H, N.
5-(3-Chloro-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-2-methyloxazole (4h). Following 
general procedure C, the residue was purified by flash chromatography on silica gel using light petroleum 
ether:EtOAc 6:4 as eluent, affording compound 4h as a white solid. Yield: 59%, mp 150–152 °C. 1H-NMR (CDCl3) 
δ : 2.64 (s, 3H), 3.81 (s, 6H), 3.85 (s, 3H), 3.88 (s, 3H), 6.91 (s, 2H), 6.92 (d, J = 8.8 Hz, 1H), 7.49 (dd, J = 8.8 and 
2.0 Hz, 1H), 7.07 (d, J = 2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ : 13.90, 56.11 (2C), 56.21, 60.94, 104.72 (2C), 
111.83, 122.28, 122.65, 126.29, 127.23, 128.41, 134.23, 137.97, 143.76, 153.33 (2C), 155.03, 160.09. MS (ESI): 
[M]+ = 389.4. Anal. (C20H20ClNO5) C, H, N.
4-(3,4,5-Trimethoxyphenyl)-5-(4-ethoxyphenyl)-2-methyloxazole (4i). Following general proce-
dure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 6:4 as 
eluent, affording compound 4i as a white solid. Yield: 65%, mp 95–97 °C. 1H-NMR (CDCl3) δ : 1.43 (t, J = 7.0 Hz, 
3H), 2.64 (s, 3H), 3.79 (s, 6H), 3.83 (s, 3H), 4.05 (q, J = 7.0 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.92 (s, 2H), 7.53 (d, 
J = 8.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ : 14.03, 14.83, 56.14 (2C), 61.01, 63.62, 104.73 (2C), 114.57 (2C), 
122.44, 128.01, 128.43 (2C), 133.61, 137.72, 145.35, 153.32 (2C), 159.25, 159.72. MS (ESI): [M]+ = 369.7. Anal. 
(C21H23NO5) C, H, N.
5-(3-Chloro-4-ethoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-2-methyloxazole (4j). Following 
general procedure C, the residue was purified by flash chromatography on silica gel using light petroleum 
ether:EtOAc 6:4 as eluent, affording compound 4j as a cream-colored solid. Yield: 63%, mp 124–126 °C. 1H-NMR 
(CDCl3) δ : 1.49 (t, J = 6.8 Hz, 3H), 2.60 (s, 3H), 3.80 (s, 6H), 3.84 (s, 3H), 4.14 (q, J = 6.8 Hz, 2H), 6.90 (m, 3H), 
7.44 (dd, J = 8.4 and 2.4 Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ : 13.93, 14.70, 56.31 (2C), 
61.05, 64.95, 104.91 (2C), 113.03, 121.56, 123.16, 126.50, 128.64, 130.04, 133.34, 138.84, 144.27, 153.51 (2C), 
154.93, 160.66. MS (ESI): [M]+ = 403.5. Anal. (C21H22ClNO5) C, H, N.
5-(3,4,5-Trimethoxyphenyl)-2-methyl-4-(naphthalen-3-yl)oxazole (5a). Following general pro-
cedure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 6:4 as 
eluent, affording compound 5a as a white solid. Yield: 63%, mp 95–97 °C. 1H-NMR (CDCl3) δ : 2.60 (s, 3H), 3.72 
(s, 6H), 3.89 (s, 3H), 6.86 (s, 2H), 7.49 (m, 2H), 7.83 (m, 4H), 8.28 (s, 1H). 13C NMR (100 MHz, CDCl3) δ : 15.46, 
56.38 (2C), 61.08, 104.16, 104.67, 124.18, 126.02, 126.48, 127.52, 127.79, 128.08, 128.34, 129.41, 133.13, 133.50, 
134.54, 137.66, 138.51, 145.86, 153.45 (2C), 160.44. MS (ESI): [M]+ = 375.6. Anal. (C23H21NO4) C, H, N.
4-(4-Fluorophenyl)-5-(3,4,5-trimethoxyphenyl)-2-methyloxazole (5b). Following general proce-
dure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 1:1 
as eluent, affording compound 5b as a white solid. Yield: 63%, mp 132–133 °C. 1H-NMR (CDCl3) δ : 2.66 (s, 
3H), 3.72 (s, 6H), 3.88 (s, 3H), 6.76 (s, 2H), 7.05 (t, J = 8.6Hz, 2H), 7.65 (dd, J = 8.8 and 8.6 Hz, 2H). 13C NMR 
(100 MHz, CDCl3) δ : 14.21, 56.20 (2C), 61.05, 103.68 (2C), 115.47 (2C), 124.10, 128.46, 130.06 (2C), 133.76, 
138.37, 145.22, 153.46 (2C), 160.19, 163.86. MS (ESI): [M]+ = 343.7. Anal. (C19H18FNO4) C, H, N.
4-(4-Chlorophenyl)-5-(3,4,5-trimethoxyphenyl)-2-methyloxazole (5c). Following general proce-
dure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 7:3 as 
eluent, affording compound 5c as a white solid. Yield: 58%, mp 149–151 °C. 1H-NMR (CDCl3) δ : 2.61 (s, 3H), 3.77 
(s, 6H), 3.89 (s, 3H), 6.77 (s, 2H), 7.33 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 
: 13.75, 56.29 (2C), 61.04, 104.00 (2C), 123.86, 128.78 (2C), 129.41 (2C), 130.59, 133.34, 134.07, 138.61, 145.67, 
153.50 (2C), 160.35. MS (ESI): [M]+ = 359.6. Anal. (C19H18ClNO4) C, H, N.
5-(3,4,5-Trimethoxyphenyl)-2-methyl-4-p-tolyloxazole (5d). Following general procedure C, the 
residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 6:4 as eluent, afford-
ing compound 5d as a white solid. Yield: 55%, mp 128–129 °C. 1H-NMR (CDCl3) δ : 2.37 (s, 3H), 2.62 (s, 3H), 3.76 
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(s, 6H), 3.88 (s, 3H), 6.81 (s, 2H), 7.17 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H). 13C NMR (100 MHz, CDCl3) 
δ : 14.08, 21.41, 56.16, 56.38, 61.05, 103.65 (2C), 104.68, 124.52, 127.98, 129.20, 129.44, 134.80, 137.67, 138.05, 
138.16, 144.88, 153.37, 153.46, 159.95. MS (ESI): [M]+ = 339.7. Anal. (C20H21NO4) C, H, N.
5-(3,4,5-Trimethoxyphenyl)-4-(4-methoxyphenyl)-2-methyloxazole (5e). Following general 
procedure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 
7:3 as eluent, affording compound 5e as a white solid. Yield: 62%, mp 108–110 °C. 1H-NMR (CDCl3) δ : 2.64 (s, 
3H), 3.77 (s, 6H), 3.78 (s, 3H), 3.83 (s, 3H), 6.80 (s, 2H), 6.90 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.8 Hz, 2H). 13C 
NMR (100 MHz, CDCl3) δ : 14.18, 55.35, 56.16 (2C), 61.00, 103.69 (2C), 114.22 (2C), 122.84, 128.45, 129.63 (2C), 
132.01, 139.21, 145.21, 153.49 (2C), 160.24, 161.11. MS (ESI): [M]+ = 355.5. Anal. (C20H21NO5) C, H, N.
4-(4-Ethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-2-methyloxazole (5f). Following general pro-
cedure C, the residue was purified by flash chromatography on silica gel using light petroleum ether:EtOAc 
6:4 as eluent, affording compound 5f as a white solid. Yield: 68%, mp 116–118 °C. 1H-NMR (CDCl3) δ : 1.39 (t, 
J = 6.8 Hz, 3H), 2.63 (s, 3H), 3.76 (s, 6H), 3.83 (s, 3H), 4.04 (q, J = 6.8 Hz, 2H), 6.81 (s, 2H), 6.89 (d, J = 8.8 Hz, 2H), 
7.59 (d, J = 8.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ : 12.34, 15.00, 56.37 (2C), 61.19, 63.74, 103.74 (2C), 104.84, 
114.72 (2C), 124.38, 129.69 (2C), 144.78, 147.23, 153.56 (2C), 160.13, 160.98, 171.03. MS (ESI): [M]+ = 369.5. 
Anal. (C21H23NO5) C, H, N.
Molecular modeling. All molecular modeling studies were performed on a MacPro dual 2.66 GHz Xeon 
running Ubuntu 14.04. The tubulin structure was downloaded from the PDB data bank (http://www.rcsb.org/; 
PDB code 1SA0)38. Hydrogen atoms were added to the protein, using the Protonate 3D routine of the Molecular 
Operating Environment (MOE)39. Ligand structures were built with MOE and minimized using the MMFF94x 
force field until a RMSD gradient of 0.05 kcal mol−1 Å−1 was reached. The docking simulations were performed 
using PLANTS40.
Biological assays
Materials and Methods. Cell growth conditions and antiproliferative assay. Human T-cell leukemia 
(Jurkat) and human B-cell leukemia (SEM and RS4;11) cells were grown in RPMI-1640 medium (Gibco, Milano, 
Italy). Breast adenocarcinoma (MCF-7), human cervix carcinoma (HeLa), human lung adenocarcinoma (A549) 
and human colon adenocarcinoma (HT-29) cells were grown in DMEM medium (Gibco, Milano, Italy), all sup-
plemented with 115 units/mL penicillin G (Gibco, Milano, Italy), 115 μg/mL streptomycin (Invitrogen, Milano, 
Italy), and 10% fetal bovine serum (FBS; Invitrogen, Milano, Italy). Stock solutions (10 mM) of the different com-
pounds were obtained by dissolving them in DMSO. Individual wells of a 96-well tissue culture microtiter plate 
were inoculated with 100 μ L of complete medium containing 8 × 103 cells. The plates were incubated at 37 °C in a 
humidified 5% CO2 incubator for 18 h prior to the experiments. After medium removal, 100 μ L of fresh medium 
containing the test compound at different concentrations was added to each well in triplicate and incubated 
at 37 °C for 72 h. The percentage of DMSO in the medium never exceeded 0.25%. This was also the maximum 
DMSO concentration in all cell-based assays described below. Cell viability was assayed by the MTT test as pre-
viously described.21 The IC50 was defined as the compound concentration required to inhibit cell proliferation 
by 50%, in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% 
viability.
Peripheral blood lymphocytes (PBL) from healthy donors were obtained from human peripheral blood (leu-
cocyte rich plasma- buffy coats) from healthy volunteers using the Lymphoprep (Fresenius KABI Norge AS) 
gradient density centrifugation.
Buffy coats were obtained from the Blood Transfusion Service, Azienda Ospedaliera of Padova and provided 
at this institution for research purposes. Therefore, no informed consent was further needed. In addition, buffy 
coats were provided without identifiers. The experimental procedures were carried out in strict accordance with 
approved guidelines.
After extensive washing, cells were resuspended (1.0 × 106 cells/mL) in RPMI-1640 with 10% FBS and incu-
bated overnight. For cytotoxicity evaluations in proliferating PBL cultures, non-adherent cells were resuspended 
at 5 × 105 cells/mL in growth medium, containing 2.5 μg/mL PHA (Irvine Scientific). Different concentrations of 
the test compounds were added, and viability was determined 72 h later by the MTT test. For cytotoxicity evalu-
ations in resting PBL cultures, non-adherent cells were resuspended (5 × 105 cells/mL) and treated for 72 h with 
the test compounds, as described above.
Effects on tubulin polymerization and on colchicine binding to tubulin. To evaluate the effect of the compounds 
on tubulin assembly in vitro41, varying concentrations of compounds were preincubated with 10 μ M bovine brain 
tubulin in 0.8 M monosodium glutamate (pH adjusted to 6.6 with HCl in a 2.0 M stock solution) at 30 ̊ C and then 
cooled to 0 ˚C. After addition of 0.4 mM GTP, the mixtures were transferred to 0 °C cuvettes in a recording spec-
trophotometer and warmed to 30 °C. Tubulin assembly was followed turbidimetrically at 350 nm. The IC50 was 
defined as the compound concentration that inhibited the extent of assembly by 50% after a 20 min incubation. 
The capacity of the test compounds to inhibit colchicine binding to tubulin was measured as described42, except 
that the reaction mixtures contained 1 μ M tubulin, 5 μ M [3H]colchicine and 1 or 5 μ M test compound.
Flow cytometric analysis of cell cycle distribution. 5 × 105 HeLa or Jurkat cells were treated with different con-
centrations of the test compounds for 24 h. After the incubation period, the cells were collected, centrifuged, 
and fixed with ice-cold ethanol (70%). The cells were then treated with lysis buffer containing RNase A and 0.1% 
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Triton X-100 and then stained with PI. Samples were analyzed on a Cytomic FC500 flow cytometer (Beckman 
Coulter). DNA histograms were analyzed using MultiCycle for Windows (Phoenix Flow Systems).
Apoptosis assay. Cell death was determined by flow cytometry of cells double stained with annexin V/FITC and 
PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to measure the surface exposure of PS on apoptotic 
cells according to the manufacturer’s instructions (Annexin-V Fluos, Roche Diagnostics).
Western blot analysis. HeLa cells were incubated in the presence of 4i and, after different times, were collected, 
centrifuged, and washed two times with ice cold phosphate buffered saline (PBS). The pellet was then resus-
pended in lysis buffer. After the cells were lysed on ice for 30 min, lysates were centrifuged at 15000× g at 4 °C 
for 10 min. The protein concentration in the supernatant was determined using the BCA Protein Assay (Pierce, 
Italy). Equal amounts of protein (10 μ g) were resolved using sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (Criterion Precast, BioRad, Italy) and transferred to a PVDF Hybond-P membrane (GE 
Healthcare). Membranes were blocked with a bovine serum albumin solution (5% in Tween PBS 1X), the mem-
branes being gently rotated overnight at 4 °C. Membranes were then incubated with primary antibodies against 
caspase-9, PARP, cdc25c, p-H2AXSer139, cyclin B, p-cdc2Tyr15 (all from Cell Signaling) or β -actin (Sigma-Aldrich) 
for 2 h at room temperature. Membranes were next incubated with peroxidase labeled secondary antibodies for 
60 min. All membranes were visualized using ECL Select (GE Healthcare), and images were acquired using an 
Uvitec-Alliance imaging system (Uvitec, Cambridge, UK). To ensure equal protein loading, each membrane was 
stripped and reprobed with anti-β -actin antibody.
Antivascular activity. HUVECs were prepared from human umbilical cord veins, as previously described43. The 
adherent cells were maintained in M200 medium supplemented with LSGS (Low Serum Growth Supplement), 
containing FBS, hydrocortisone, hEGF, bFGF, heparin, gentamycin/amphotericin (Life Technologies, Monza, 
Italy). Once confluent, the cells were detached by a trypsin–EDTA solution and used in experiments from the 
first to sixth passages.
The motility assay for HUVECs was based on “scratch” wounding of a confluent monolayer35. Briefly, 
HUVECs (1x105) were seeded onto 6-well plates coated with 0.1% collagen type I (BD Biosciences, Italy) in 
complete medium until a confluent monolayer was formed. The cells were wounded using a pipette tip, and wells 
were washed with PBS to remove undetached cells. Then, the cells were treated with the test compounds, and, 
at different times from the scratch, the cells were photographed under a light microscope. At all indicated time 
points, the wound width was measured in four areas and compared with the initial width.
Matrigel matrix (Basement Membrane Matrix, BD Biosciences, Italy) was kept at 4 °C for 3 h, when 230 μ L of 
Matrigel solution was added to each well of a 24-well plate. After gelling at 37 °C for 30 min, gels were overlaid 
with 500 μ L of medium containing 6 × 104 HUVECs. The cells were incubated over Matrigel for 6 h to allow 
capillary tubes to form. Different concentrations of test compound were added in the cultures and incubated for 
different times, and the disappearance of existing vasculature was monitored and photographed (five fields for 
each well: the four quadrants and the center) at a 10x magnification. Phase contrast images were recorded using a 
digital camera and saved as TIFF files. Image analysis was carried out using ImageJ image analysis software, and 
dimensional (percent area covered by HUVECs and total length of HUVECs network per field) and topological 
parameters (number of meshes and branching points per field) were determined43. Values were expressed as per-
cent change from control cultures grown with complete medium.
In vivo animal studies. Animal experiments were approved by our local animal ethics committee (OPBA, 
Organismo Preposto al Benessere degli Animali, Università degli Studi di Brescia, Italy) and were executed in 
accordance with national guidelines and regulations. Procedures involving animals and their care conformed 
with institutional guidelines that comply with national and international laws and policies (EEC Council 
Directive 86/609, OJ L 358, 12 December 1987) and with “ARRIVE” guidelines (Animals in Research Reporting 
In Vivo Experiments). Six week old C57BL/6 mice (Charles River, Calco) were injected subcutaneously into the 
dorsolateral flank with 2.5x105 BL6-B16 murine melanoma cells in 200 μ L of PBS. When tumors were palpable, 
animals were treated intraperitoneally every other day with different doses of test compounds dissolved in 50 μ L 
of DMSO. Tumors were measured in two dimensions, and tumor volume was calculated according to the formula 
V = (D × d2)/2, where D and d are the major and minor perpendicular tumor diameters, respectively.
Statistical analysis. Unless indicated differently, the results are presented as mean ± SEM. The differences 
between different treatments were analyzed, using the two-sided Student’s t test. P values lower than 0.05 were 
considered significant.
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